Housing demand rebounded as snow effects faded, pending sales and new listings rose, and price cuts fell 1% with rates at ...
The PCE price index faces a projected 0.4% spike as Q4 2025 GDP growth slows to 3%. Read why disruption risks are very high for growth and inflation.
Q4 2026 earnings preview: hold rating as growth normalizes, guidance implies 21% YoY; weigh risks & upside catalysts. Read ...
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript February 12, 2026 Ultragenyx Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-1.29 EPS, expectations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results